Alphabet's Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?

Alphabet's venture capital arms, GV and CapitalG, manage a public equity portfolio valued at $2.5 billion to $3 billion across 37 stocks, heavily weighted towards healthcare and biotech, with Planet Labs being its largest holding. In the third quarter, Alphabet exited Verve Therapeutics and strategically added Figma, a cloud-based interface design platform, likely for synergy with its UI/UX ecosystem and potential AI integration, alongside BridgeBio Oncology Therapeutics, a precision oncology developer, aligning with its broader healthcare AI initiatives. This activity highlights Alphabet's diversified investment strategy, leveraging its venture capital arms to support strategic adjacencies and emerging technologies beyond its core businesses.

Analysis

Alphabet's venture capital arms, GV and CapitalG, actively manage a public equity portfolio valued between $2.5 billion and $3 billion, comprising 37 stocks with a significant tilt towards healthcare and biotech. This strategic portfolio saw one exit in Q3, Verve Therapeutics, acquired by Eli Lilly for $1.3 billion, while adding two new positions: Figma and BridgeBio Oncology Therapeutics. This activity underscores Alphabet's diversified investment approach beyond its core operations.

The investment in Figma (FIG), a cloud-based interface design platform, aligns with Alphabet's internal UI/UX needs for products like Android and Workspace, and its broader AI push, potentially integrating generative design elements. Despite being down 66% since its July IPO, Figma shows steady subscription revenue growth, though it faces competition from Adobe's XD and economic headwinds. Alphabet holds approximately $8.3 million in Figma shares, indicating a strategic, rather than purely financial, stake.

Concurrently, Alphabet's entry into BridgeBio Oncology Therapeutics (BBOT) underscores its continued focus on healthcare, particularly oncology, complementing its Verily initiatives in AI-driven drug discovery. This move, following the exit of another biotech, suggests a strategic pivot towards the $250 billion oncology market. BridgeBio offers high upside potential from positive trial data but carries significant risks associated with clinical development and regulatory hurdles. Alphabet's stake in BBOT is valued at over $37 million.

These investments highlight Alphabet's strategy to leverage its venture capital for synergistic opportunities and exposure to high-growth, innovation-driven sectors like AI-enhanced design and precision oncology, extending beyond its core search and cloud businesses, reflecting a mildly positive sentiment towards Alphabet's strategic foresight.

Key Decisions for Investors

• Investors should view Alphabet's venture investments as a signal of strategic areas of interest, particularly in AI-enhanced design and precision oncology, which could offer long-term growth opportunities.
• For Figma (FIG), monitor its post-IPO revenue stability and competitive positioning against Adobe, considering its potential for AI integration within design workflows.
• For BridgeBio Oncology Therapeutics (BBOT), assess clinical trial outcomes and regulatory progress, acknowledging the inherent volatility and speculative nature of early-stage biotech, despite its exposure to the growing oncology market.